169 related articles for article (PubMed ID: 32955081)
1. Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.
Wang M; Zhao Y; Hu W; Zhao D; Zhang Y; Wang T; Zheng Z; Li X; Zeng S; Liu Z; Lu L; Wan Z; Hu K
Clin Infect Dis; 2021 Dec; 73(11):e4012-e4019. PubMed ID: 32955081
[TBL] [Abstract][Full Text] [Related]
2. An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection.
Pan Z; Wan Z; Wang Y; Zha S; Zhang J; Chen H; Hu K
Front Med (Lausanne); 2023; 10():1218102. PubMed ID: 37534317
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
4. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Hu K; Wang M; Zhao Y; Zhang Y; Wang T; Zheng Z; Li X; Zeng S; Zhao D; Li H; Xu K; Lan K
Virol Sin; 2020 Dec; 35(6):725-733. PubMed ID: 32696396
[TBL] [Abstract][Full Text] [Related]
5. Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa.
Meiring S; Tempia S; Bhiman JN; Buys A; Kleynhans J; Makhasi M; McMorrow M; Moyes J; Quan V; Walaza S; du Plessis M; Wolter N; von Gottberg A; Cohen C;
Clin Infect Dis; 2022 Aug; 75(1):e144-e156. PubMed ID: 35134129
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients.
Buetti N; Trimboli P; Mazzuchelli T; Lo Priore E; Balmelli C; Trkola A; Conti M; Martinetti G; Elzi L; Ceschi A; Consonni V; Ogna A; Forni-Ogna V; Bernasconi E
Endocrine; 2020 Dec; 70(3):454-460. PubMed ID: 32870469
[TBL] [Abstract][Full Text] [Related]
7. Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study.
Xu N; Pan J; Sun L; Zhou C; Huang S; Chen M; Zhang J; Zhu T; Li J; Zhang H; Gao Y
Front Immunol; 2022; 13():967716. PubMed ID: 35990674
[TBL] [Abstract][Full Text] [Related]
8. Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial.
Tam AR; Zhang RR; Lung KC; Liu R; Leung KY; Liu D; Fan Y; Lu L; Lam AH; Chung TW; Yip CC; Lo J; Wu AK; Lee R; Sin S; Ng PY; Chan WM; Shum HP; Yan WW; Chan JF; Cheng VC; Lau CS; To KK; Chan KH; Yuen KY; Hung IF
Clin Infect Dis; 2023 Feb; 76(3):e216-e226. PubMed ID: 35762834
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study.
Shi D; Wu W; Wang Q; Xu K; Xie J; Wu J; Lv L; Sheng J; Guo J; Wang K; Fang D; Li Y; Li L
J Infect Dis; 2020 Aug; 222(6):910-918. PubMed ID: 32614392
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study.
Wang Q; Guo H; Li Y; Jian X; Hou X; Zhong N; Fei J; Su D; Bian Z; Zhang Y; Hu Y; Sun Y; Yu X; Li Y; Jiang B; Li Y; Qin F; Wu Y; Gao Y; Hu Z
Front Pharmacol; 2021; 12():581833. PubMed ID: 34276351
[No Abstract] [Full Text] [Related]
12. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).
Xu K; Chen Y; Yuan J; Yi P; Ding C; Wu W; Li Y; Ni Q; Zou R; Li X; Xu M; Zhang Y; Zhao H; Zhang X; Yu L; Su J; Lang G; Liu J; Wu X; Guo Y; Tao J; Shi D; Yu L; Cao Q; Ruan B; Liu L; Wang Z; Xu Y; Liu Y; Sheng J; Li L
Clin Infect Dis; 2020 Jul; 71(15):799-806. PubMed ID: 32271376
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Kralj-Hans I; Li K; Wesek A; Lamorgese A; Omar F; Ranasinghe K; McGee M; Brack K; Li S; Aggarwal R; Bulle A; Kodre A; Sharma S; Fluck D; John I; Sharma P; Belsey JD; Li L; Seshasai SRK; Li HL; Marczin N; Chen Z;
BMJ Open; 2023 Apr; 13(4):e068179. PubMed ID: 37055207
[TBL] [Abstract][Full Text] [Related]
14. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid, oseltamivir and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019.
Hu F; Yin G; Chen Y; Song J; Ye M; Liu J; Chen C; Song Y; Tang X; Zhang Y
Clin Respir J; 2020 Nov; 14(11):1067-1075. PubMed ID: 32750201
[TBL] [Abstract][Full Text] [Related]
16. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19.
Chen X; Zhu B; Hong W; Zeng J; He X; Chen J; Zheng H; Qiu S; Deng Y; Chan JCN; Wang J; Zhang Y
Int J Infect Dis; 2020 Sep; 98():252-260. PubMed ID: 32619760
[TBL] [Abstract][Full Text] [Related]
17. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.
Nakajima Y; Ogai A; Furukawa K; Arai R; Anan R; Nakano Y; Kurihara Y; Shimizu H; Misaki T; Okabe N
J Infect Chemother; 2021 Feb; 27(2):387-389. PubMed ID: 33328135
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with a prolonged negative conversion of viral RNA in patients with COVID-19.
Bennasrallah C; Zemni I; Dhouib W; Sriha H; Mezhoud N; Bouslama S; Taboubi W; Beji MO; Kacem M; Abroug H; Fredj MB; Loussaief C; Belguith AS
Int J Infect Dis; 2021 Apr; 105():463-469. PubMed ID: 33647508
[TBL] [Abstract][Full Text] [Related]
19. Recurrent SARS-CoV-2 RNA positivity and prolonged viral shedding in a patient with COVID-19: a case report.
Xiao CH; Chen LF; Li Y
BMC Infect Dis; 2021 Oct; 21(1):1076. PubMed ID: 34663257
[TBL] [Abstract][Full Text] [Related]
20. Chronic rhinosinusitis is associated with prolonged SARS-CoV-2 RNA shedding in upper respiratory tract samples: A case-control study.
Recalde-Zamacona B; Tomás-Velázquez A; Campo A; Satrústegui-Alzugaray B; Fernández-Alonso M; Iñigo M; Rodríguez-Mateos M; Di Frisco M; Felgueroso C; Bertó J; Marín-Oto M; Alcaide AB; Zulueta JJ; Seijo L; Landecho MF
J Intern Med; 2021 Jun; 289(6):921-925. PubMed ID: 33372300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
